A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease

Phase 3

UCB Pharma

Certolizumab Pegol